Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19

被引：0
|
作者：
Cawcutt, Kelly A. [1 ]
Kalil, Andre C. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE 68198 USA
来源：
CRITICAL CARE MEDICINE | 2023年 / 51卷 / 03期
关键词：
baricitinib; COVID-19; critical illness; immunomodulators; tocilizumab;
D O I：
10.1097/CCM.0000000000005757
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：413 / 415
页数：3
相关论文
共 50 条
  • [1] USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS
    Xibille Friedmann, D. X.
    Carrillo Vazquez, S. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 899 - 900
  • [2] Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Reid, Nancy Kierstin
    Joyner, Kayla Rena
    Lewis-Wolfson, Temeka Dawn
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (07) : 769 - 775
  • [3] BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19
    Lewis-Wolfson, Temeka
    Joyner, Kayla
    Reid, Nancy
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 191 - 191
  • [4] Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
    Rosas, I. O.
    Brau, N.
    Waters, M.
    Go, R. C.
    Hunter, B. D.
    Bhagani, S.
    Skiest, D.
    Aziz, M. S.
    Cooper, N.
    Douglas, I. S.
    Savic, S.
    Youngstein, T.
    Del Sorbo, L.
    Gracian, A. Cubillo
    De la Zerda, D. J.
    Ustianowski, A.
    Bao, M.
    Dimonaco, S.
    Graham, E.
    Matharu, B.
    Spotswood, H.
    Tsai, L.
    Malhotra, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1503 - 1516
  • [5] Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Lewis-Wolfson, Temeka Dawn
    Joyner, Kayla Rena
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (09) : 1118 - 1119
  • [6] Comment: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (09) : 1117 - 1117
  • [7] Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
    Karampitsakos, Theodoros
    Papaioannou, Ourania
    Tsiri, Panagiota
    Katsaras, Matthaios
    Katsimpris, Andreas
    Kalogeropoulos, Andreas P.
    Malakounidou, Elli
    Zarkadi, Eirini
    Tsirikos, Georgios
    Georgiopoulou, Vasiliki
    Sotiropoulou, Vasilina
    Koulousousa, Electra
    Chourpiliadi, Charikleia
    Matsioulas, Apostolos
    Lagadinou, Maria
    Sampsonas, Fotios
    Akinosoglou, Karolina
    Marangos, Markos
    Tzouvelekis, Argyris
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (03) : 372 - 378
  • [8] Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity
    Troyer, Bradley S.
    Scherrer, Nicole Kovacic
    Garavaglia, Jeffrey
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (03) : 632 - 636
  • [9] Adverse Effects of Tocilizumab Versus Baricitinib in Severe COVID-19
    Leaf, David E.
    Gordon, Anthony C.
    Lawler, Patrick R.
    CRITICAL CARE MEDICINE, 2023, 51 (09) : E184 - E185
  • [10] Tocilizumab for hospitalized patients with COVID-19
    Afra, Kevin
    Chen, Luke Y. C.
    Sweet, David
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (15) : E521 - E521
12345